Analysts sanguine on US market, as Trumpcare flounders

Financial analyst Morningstar has expressed confidence in the strength of the US healthcare market, as “continued abatement of concerns over branded drug prices helps valuations.”

While a series of strident tweets on drug pricing from the incoming US President before and after his inauguration rattled the market, attention has drifted away from the issue in recent months. Some say a return to more bullish pricing practices may be on the horizon.

Chief financial analyst Damien Conover picks out Swiss giant Roche (SIX: ROG) and Allergan (NYSE: AGN) as particularly of interest, as well as pharmacy middleman Express Scripts (Nasdaq: ESRX).